• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHANG Jing, LIU Xin, XU Chun. Analysis of the progress and research hotspots of “Pharmacology and Toxicology” in Chinese universities based on the databases[J]. Journal of China Pharmaceutical University, 2020, 51(6): 748-758. DOI: 10.11665/j.issn.1000-5048.20200615
Citation: ZHANG Jing, LIU Xin, XU Chun. Analysis of the progress and research hotspots of “Pharmacology and Toxicology” in Chinese universities based on the databases[J]. Journal of China Pharmaceutical University, 2020, 51(6): 748-758. DOI: 10.11665/j.issn.1000-5048.20200615
shu

Analysis of the progress and research hotspots of “Pharmacology and Toxicology” in Chinese universities based on the databases

Funds: This study was supported by the Key Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province (No. 2018SJZDI127)
More Information
  • Received Date: August 16, 2020
  • Revised Date: October 12, 2020
    Graphical Abstract
    • Abstract
  • This paper using ESI,JCR,InCites,and WoS database,the data of Pharmacology and Toxicology were retrieved,and the development status of domestic universities was analyzed by using bibliometrics,statistics and other analysis methods. Taking Chinese universities ranked in the top 100 of ESI as an example,the multi-index status of the subject was analyzed in detail,and the publication category,citation of the highly cited papers in domestic universities were analyzed emphatically on journals,publishing institutions and teams,research frontiers and hot spots,etc. In order to provide data and decision-making references for the construction and development of Pharmacology and Toxicology,the domestic research status and frontier hot spots of Pharmacology and Toxicology were summarized.
    • FullText(HTML)
    • References (16)
  • [1]
    .（2017-01-25）［2020-08-15］. http：//edu.people.com.cn/n1/2017/0125/c1006-29049551.html.
    [2]
    Hu JH. The influence of “Double First-class” construction on the discipline development in China''''s universities［J］. Jiangsu Higher Educ（江苏高教），2018（7）：5?8，13.
    [3]
    Zhang JL，Chen TZ. On the discipline development planning in the construction of “Double First-Class”：strategy，management，and effectiveness—case studies of two institutions building into world-class universities［J］. China Higher Educ Res（中国高教研究），2018（7）：22?29.
    [4]
    Liu BH，Zhang HR，Wang HW. The contrastive analysis of mathematical subject data based on ESI and thoughts on discipline construction—taking the mathematics of Wuhan University as an example［J］. Document Inform Knowl（图书情报知识），2017（1）：114?122.
    [5]
    Song LP，Wang JF. An empirical study of scientific evaluation based on the correlation between CNCI and peer review［J］. Lib Inform Ser（图书情报工作），2018，62（18）：122?128.
    [6]
    Yang FJ，Liang Z，Xue L，et al. Assessing the effects of the Chinese state key laboratory initiative［J］. Sci Sci Managem S& T（科学学与科学技术管理），2019，40（2）：26?39.
    [7]
    Ding S. Analysis on the influencing factors of scientific research development in affiliated hospitals of colleges and universities and countermeasures［C］. Proceedings of the Third National Forum on Medical Research Management and Annual Meeting of Jiangsu Province. Nanjing，China，2011.
    [8]
    Shen TP，Yang ST，Chu JW. Hotspot of knowledge chain research based on the co-words analysis［J］. New Cent Lib（新世纪图书馆），2014（1）：88?92.
    [9]
    Mao SR，Sun W，Kissel T. Chitosan-based formulations for delivery of DNA and siRNA［J］. Adv Drug Deliv Rev，2010，62（1）：12?27.
    [10]
    Banerjee A，Qi JP，Gogoi R，et al. Role of nanoparticle size，shape and surface chemistry in oral drug delivery［J］. J Control Release，2016，238：176?185.
    [11]
    Zhang SY，Liu YJ，Gan Y，et al. Conjugates of TAT and folate with DOX-loaded chitosan micelles offer effective intracellular delivery ability［J］. Pharm Dev Technol，2019，24（2）：253?261.
    [12]
    Wei X，Yang X，Han ZP，et al. Mesenchymal stem cells：a new trend for cell therapy［J］. Acta Pharm Sin（药学学报），2013，34（6）：747?754.
    [13]
    Chen XM，Song EW. Turning foes to friends：targeting cancer-associated fibroblasts［J］. Nat Rev Drug Discov，2019，18（2）：99?115.
    [14]
    Guo ZR. The modification of natural products for medical use［J］. Acta Pharma Sin B，2017，7（2）：119?136.
    [15]
    Williamson EM，Liu XM，Izzo AA. Trends in use，pharmacology，and clinical applications of emerging herbal nutraceuticals［J］. Brit J Pharmacol，2020，177（6）：1227?1240.
    [16]
    Zhang Y，Huo MR，Zhou JP. et al. DDSolver：an add-in program for modeling and comparison of drug dissolution profiles［J］. The AAPS J，2010，12（3）：263?271.
    • Related Articles

  • Related Articles

    [1]CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
    [2]ZHANG Yuxin, DING Ming, LIU Jun. Research progress of proximity labeling technology based on biotin ligase in proteomics[J]. Journal of China Pharmaceutical University, 2022, 53(1): 18-24. DOI: 10.11665/j.issn.1000-5048.20220103
    [3]MO Xiaofei, XU Xiaoli, WANG Yalou, YOU Qidong. Advances in the HIF-1α/p300 protein-protein interaction inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(5): 515-522. DOI: 10.11665/j.issn.1000-5048.20170502
    [4]LIU Fang, SUN Haopeng, YOU Qidong. Advances in small-molecule inhibitors targeting Hsp90-Cdc37 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2015, 46(3): 272-278. DOI: 10.11665/j.issn.1000-5048.20150303
    [5]The Effect of Inducer on Enzyme Activity of Dihydropyri midinase[J]. Journal of China Pharmaceutical University, 1999, (3): 60-63.
    [6]Purification and Characterization of Potent Fibrinolytic Enzyme from Earthworm[J]. Journal of China Pharmaceutical University, 1997, (6): 48-51.
    [7]Pharmacokinetic Studies of Nevin Fibrinolytic Enzyme[J]. Journal of China Pharmaceutical University, 1997, (2): 107-110.
    [8]Effect of Astragalus on Fluidity of Lipid Regions and Conformation of Protein of Human Erythrocyte Membranes[J]. Journal of China Pharmaceutical University, 1994, (4): 49-52.
    [9]Interaction of Four Berbamine Derivatives with Erythrocyte Membrane Ca~(2 )-Mg~(2 )-ATPase[J]. Journal of China Pharmaceutical University, 1993, (5): 304-307.
    [10]Wu Wutong. Advances in enzyme drugs[J]. Journal of China Pharmaceutical University, 1982, (3): 59-64.

  • Cited by

    Periodical cited type(3)

    1. 李锦华，祁萍，乔慧. ALK-TKI耐药后获得性RET融合晚期非小细胞肺癌1例报道并文献复习. 肿瘤防治研究. 2024(08): 703-706 .
    2. 王瑞峰，赵相欣，孙印，秦桥花，赵冬梅. 降解FAK的PROTAC分子的设计合成及生物活性研究. 中国药物化学杂志. 2023(07): 481-489 .
    3. 王梓灵，郭瑜婕，朱芸芸，陈乐，吴婷，刘大会，黄必胜，杜鸿志. 金花茶有效部位抑制表皮生长因子受体(EGFR)抗非小细胞肺癌的作用机制研究. 中国中药杂志. 2021(20): 5362-5371 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (252) PDF downloads (819) Cited by(5)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365379

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return